Compare CEPU & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CEPU | DFTX |
|---|---|---|
| Founded | 1989 | N/A |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2017 | N/A |
| Metric | CEPU | DFTX |
|---|---|---|
| Price | $15.07 | $23.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $17.50 | ★ $38.50 |
| AVG Volume (30 Days) | 321.8K | ★ 1.5M |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $14.62 |
| 52 Week High | $18.50 | $26.25 |
| Indicator | CEPU | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 56.46 |
| Support Level | $14.84 | $16.37 |
| Resistance Level | $15.56 | $26.25 |
| Average True Range (ATR) | 0.70 | 1.10 |
| MACD | 0.19 | 0.13 |
| Stochastic Oscillator | 55.77 | 72.66 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).